Roller Coaster Path to Approval for Bristol-Myers Squibb Company, Pfizer Inc.'s Eliquis Uncovered by FDA Documents
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
After the presentation and publication of the pivotal ARISTOTLE trial, the novel anticoagulant apixaban (Eliquis, Pfizer PFE +0.66% and BristolMyers Squibb) was widely expected to be a blockbuster. But then it got bogged down at the FDA where initial hopes for a speedy approval were dashed after highly critical reviews. Ultimately approval of the drug was delayed for 9 months past the original deadline as a result of both a PDUFA date extension and a complete response letter from the FDA. Now an article by Sue Sutter in Pharmaceutical Approvals Monthly, based on documents posted by the FDA on its website, offers an inside look at the drug’s roller coaster ride through the FDA.
Help employers find you! Check out all the jobs and post your resume.
After the presentation and publication of the pivotal ARISTOTLE trial, the novel anticoagulant apixaban (Eliquis, Pfizer PFE +0.66% and BristolMyers Squibb) was widely expected to be a blockbuster. But then it got bogged down at the FDA where initial hopes for a speedy approval were dashed after highly critical reviews. Ultimately approval of the drug was delayed for 9 months past the original deadline as a result of both a PDUFA date extension and a complete response letter from the FDA. Now an article by Sue Sutter in Pharmaceutical Approvals Monthly, based on documents posted by the FDA on its website, offers an inside look at the drug’s roller coaster ride through the FDA.
Help employers find you! Check out all the jobs and post your resume.